Skip to main content

Table 2 Summary of studies which investigated treatment uptake

From: A systematic review of community based hepatitis C treatment

Study

Study population and policy for initiating treatment (if included in publication)

Facility

N

OST (%)

Active illicit substance use

Treatment uptake

n (%)

Bruce

HCV infection +/− HIV

Attendance at OST clinic

Rx according to published guidelines and the same in both facilities

Tertiary

9

100

Opioid negative on urine toxicology in past 30 days

4 (44)

Primary

12

100

Opioid negative on urine toxicology in past 30 days

12 (100)

Gigi

HCV antibody positive

Attended Liver clinic or OST clinic

Policy for Rx initiation not published

Tertiary

643

0

Nil

276 (43)

Primary

204

100

Nil

17 (8)

Kramer

HCV infection

Designated Primary Care Provider

Majority of care from one Veterans Affairs facility

Rx indicated if more than portal fibrosis and no contraindications (including no active illicit drug use)

Specialist clinic

24,853

N/P

N/P

3537 (14)

Primary clinic

1929

N/P

N/P

251 (13)

Kuo

HCV antibody positive

Participation in screening program

Pre-intervention Rx if: ALT >40 (once) and > F1 or HCV RNA positive

Post intervention Rx if ALT >80 (twice) and > F1

Pre intervention

18

N/P

N/P

4 (22)

Post intervention

N/P

N/P

3 (19)

Moriarty

HCV infection

Attendance at outreach clinic

Policy for Rx initiation not published

Tertiary

51

N/P

N/P

1 (2)

Primary

N/P

N/P

4 (8)

Moussalli

HCV infection

Attendance at OST Primary healthcare facility

Rx if > F2 fibrosis

Pre-intervention

337

N/P

N/P

2 (0.6)

Post intervention

N/P

N/P

85 (25)

  1. OST opioid substitution therapy, N/P not provided, Rx treatment